4/A: IMMUNIC COO Corrects Insider Filing, Discloses Significant Stock Option Grant and Share Purchase

IMMUNIC, Inc.'s President and COO, Jason Tardio, filed an amended Form 4 to correct an administrative error regarding a stock option grant, also confirming a recent purchase of common stock.

Summary

• Jason Tardio, President and COO of IMMUNIC, INC. (IMUX), filed a Form 4/A on June 20, 2025, to amend a previous Form 4 filed on June 9, 2025.
• The amendment was made to correct an administrative error that incorrectly reported the number of stock options granted to Mr. Tardio.
• The filing confirms the acquisition of 12,512 shares of common stock by Mr. Tardio on June 5, 2025, at a price of $0.79 per share, bringing his direct beneficial ownership to 12,512 shares.
• It also details the grant of 598,500 stock options to Mr. Tardio on June 5, 2025, with an exercise price of $0.7729 per option.
• These options will vest 25% on the first anniversary of the grant date, with the remainder vesting in equal monthly increments over the subsequent 36 months, and have an expiration date of June 5, 2035.

Sentiment

Score: 6

Explanation: The sentiment is slightly positive due to the insider's purchase of common stock and a significant option grant, which can signal confidence. The administrative error is a minor negative, but its correction is a neutral event.

Positives

• The President and COO, Jason Tardio, acquired 12,512 shares of common stock, indicating a direct investment and potential confidence in the company's future.
• A significant grant of 598,500 stock options to a key executive aligns management's incentives with shareholder value creation.

Negatives

• An administrative error in a prior SEC filing, though corrected, suggests a minor internal process oversight.

Future Outlook

The vesting schedule for the stock options, extending over 36 months after an initial one-year cliff, indicates a long-term commitment and incentive for the President and COO, aligning his future performance with the company's success.

Management Comments

• "This Form 4/A is being filed to amend the prior Form 4 filed by the Reporting Person on June 9, 2025 to correct an administrative error that incorrectly reported the number of stock options granted."

Industry Context

This filing is a standard disclosure of executive compensation and insider trading activity within the biotechnology or pharmaceutical industry, reflecting how companies incentivize and align their leadership with shareholder interests through equity grants and direct share ownership.

Stakeholder Impact

• Shareholders may view the COO's direct purchase of common stock and significant option grant as a positive signal of management's belief in the company's future prospects and commitment to long-term value creation.

Next Steps

• The granted stock options will begin vesting on the first anniversary of the grant date (June 5, 2026), with subsequent monthly vesting increments for 36 months.

Key Dates

Keywords

IMMUNIC, IMUX, Jason Tardio, SEC Form 4/A, Insider Trading, Stock Options, Common Stock, Beneficial Ownership, Executive Compensation, Biotechnology, Pharmaceuticals